舒利迭治疗稳定期慢性阻塞性肺疾病的疗效分析

Effect of Seretide in treatment of stable chronic obstructive pulmonary disease

目的探讨舒利迭治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法将我院诊治的128例稳定期COPD患者按随机数字表法分为对照组与观察组,给予对照组患者(62例)常规治疗,观察组患者(66例)在常规治疗基础上给予舒利迭吸入,疗程12周,比较两组临床症状评分、肺功能及骨密度的改变。结果治疗后6周及12周,观察组患者临床症状评分显著低于对照组(P<0.05);治疗后12周观察组肺功能指标用力呼气量(FEV)、第1秒用力呼气容积占预计值百分比(FEV1%预计值)及第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)均显著优于对照组(P<0.05);治疗期间两组骨密度与治疗前相比均无统计学差异(P>0.05)。结论舒利迭可显著改善稳定期COPD患者临床症状及肺功能,且不增加不良反应。

Objective To explore the effect of Seretide in treatment of stable chronic obstructive pulmonary disease （COPD）. Methods A total of 128 cases of stable COPD were divided into trial group （ n = 62） and control group （ n = 66） according to ran- dom number table. The control group was given routine treatment and the trial group received additionally inhaled Seretide for 12 weeks. Clinical symptom scores, lung function and bone density were compared between the two groups before and after treatment. Results The clinical symptom scores were much lower in the trial group than in the control group after 6-and 12 weeks＇ treatment （P 〈 0. 05 ） ; forced expiratory volume （FEV）, FEV1% and （FEV1/FVC）% of the trial group were all superior to that of the con- trol group after 12 weeks＇ treatment （ P 〈 0.05 ）. There were no significant difference in bone density between before and after treatment in both the two groups （P 〉 0. 05）. Conclusion Seretide applied to COPD greatly is able to improve clinical symptoms and lung function with less adverse reaction.